Dapagliflozin-¹³C₆-1

Cat. No.: HY-10450S5: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Dapagliflozin-¹³C₆-1 is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.

For research use only. We do not sell to patients.

Dapagliflozin-<sup>13</sup>C<sub>6</sub>-1 Chemical Structure

Dapagliflozin-¹³C₆-1 Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Dapagliflozin-¹³C₆-1:

Dapagliflozin In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All SGLT Isoform Specific Products:

View All Isoforms

SGLT1 SGLT2

Biological Activity
Purity & Documentation
References
Customer Review

Description	Dapagliflozin-¹³C₆-1 is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine^[1]. Dapagliflozin induces HIF1 expression and attenuates renal IR injury^[2].
Molecular Weight	414.83
Formula	C₁₅¹³C₆H₂₅ClO₆
Unlabeled CAS	461432-26-8
SMILES	O[13CH2][13C@@H]1[13C@H]([13C@@H]([13C@H]([13C@@H](O1)C2=CC(CC3=CC=C(C=C3)OCC)=C(C=C2)Cl)O)O)O
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (265 KB) Handling Instructions (2659 KB)
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief] [2]. Pelissier T, et al. The orofacial capsaicin test in rats: effects of different capsaicin concentrations and morphine. Pain. 2002 Mar;96(1-2):81-7. [Content Brief]